Abstract
Erratum to "Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: Case-study with non-replicating rotavirus (NRRV) vaccine antigens" [J Pharm Sci 110 (2021) 1042-1053
Highlights
Contents lists available at ScienceDirect Journal of Pharmaceutical Sciences journal homepage: www.jpharmsci.org
This paper was miscategorized in the March 2021 issue and should have been included under the subject category of Pharmaceutical Biotechnology with the companion article, “Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine” [J Pharm Sci 110 (2021) 1054−1066]
Erratum to “Rapid developability assessments to formulate recombinant protein antigens as stable, low-cost, multi-dose vaccine candidates: Case-study with non-replicating rotavirus (NRRV) vaccine antigens” [J Pharm Sci 110 (2021) 1042−1053]
Summary
This paper was miscategorized in the March 2021 issue and should have been included under the subject category of Pharmaceutical Biotechnology with the companion article, “Mechanism of Thimerosal-Induced Structural Destabilization of a Recombinant Rotavirus P[4] Protein Antigen Formulated as a Multi-Dose Vaccine” [J Pharm Sci 110 (2021) 1054−1066].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
